Video

Fatigue or Autoimmune Disease? Physician Talks Immunotherapy Side Effects

Author(s):

Yvonne Saenger, MD

Yvonne Saenger, director of melanoma and immunotherapy at Columbia University Medical Center, discusses the side effects patients should look out for when they are on immunotherapy, and how to determine if they are experiencing normal therapy-induced fatigue or if they are suffering from a hormone reaction and should go see their medical team.

Yvonne Saenger, director of melanoma and immunotherapy at Columbia University Medical Center, discusses the side effects patients should look out for when they are on immunotherapy, and how to determine if they are experiencing normal therapy-induced fatigue or if they are suffering from a hormone reaction and should go see their medical team at the Society for Immunotherapy of Cancer (SITC) 101 session.

Related Videos
Dr. Sattva S. Neelapu, a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Michael Bogenschutz, director of the NYU Langone Center for Psychedelic Medicine in New York,
Dr. Richard “Rick" Winneker
Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in relapsed/refractory follicular lymphoma
Image of man with grey hair.
Image of woman with blonde hair.
Image of man with grey hair.
Image of man with brown and grey hair.
Image of man with grey hair.
Image of bald man in suit.
Related Content
"FDA" text.
January 2nd 2025

Cancer Therapies Approved by the FDA in December 2024

Darlene Dobkowski, MA
The FDA approved several drugs in December for the treatment of diseases, including pancreatic adenocarcinoma, lung cancer, skin cancer and graft-versus-host disease.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Image of hands holding a pink ribbon.
December 30th 2024

Breast Cancer Journeys and the Quest to Feel Normal Again

Janet Gerlach
A patient advocate says that patients with breast cancer may find it challenging to feel "normal," but reconstruction advancements may help.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
top news text on newspaper: © emiliezhang - stock.adobe.com
December 28th 2024

Top Palliative Care Stories From 2024

Alex Biese
From the benefits of early adoption to the effectiveness of telehealth, here is what we reported about palliative care throughout the year.
white background with black text indicating FDA
December 27th 2024

Subcutaneous Opdivo Receives FDA Approval for Advanced, Metastatic Solid Tumors

Darlene Dobkowski, MA
Opdivo Qvantig received FDA approval for all previously approved indications in solid tumors.